14 w - Translate

Niraparib Market set to hit $2.8 billion by 2035

Industry revenue for Niraparib is estimated to rise to $2.8 billion by 2035 from $1.3 billion of 2024. The revenue growth of market players is expected to average at 7.1% annually for the period 2024 to 2035.

Niraparib is critical across several key applications including ovarian cancer treatment, breast cancer treatment, cancer recurrence prevention and prostate cancer treatment. The report unwinds growth & revenue expansion opportunities at Niraparib’s Product Formulation, End-Users, Therapeutic Application, Drug Availability and Patient Demographics including industry revenue forecast.

Industry Leadership and Competitive Landscape

The Niraparib market is characterized by intense competition, with a number of leading players such as GlaxoSmithKline, Tesaro Inc, Zejula, Zai Lab, Clovis Oncology, AstraZeneca, Beigene, Eli Lilly, Johnson & Johnson, Novartis, BluePrint Medicines and Gilead Sciences.
The Niraparib market is projected to expand substantially, driven by high demand in cancer therapies and technological advancements in drug development. This growth is expected to be further supported by Micro industry trends.

Moreover, the key opportunities, such as expansion into untapped markets, technological innovations in drug delivery and strategic collaborations and partnerships, are anticipated to create revenue pockets in major demand hubs including U.S., China, Japan, Germany and UK.

Regional Shifts and Evolving Supply Chains

North America and Asia-Pacific are the two most active and leading regions in the market. With challenges like high treatment cost and risk of adverse side effects, Niraparib market’s supply chain from raw material procurement / api production / formulation & processing to distribution & end-users is expected to evolve & expand further; and industry players will make strategic advancement in emerging markets including Nigeria, Indonesia and Colombia for revenue diversification and TAM expansion.

Detailed Analysis - https://datastringconsulting.c....om/industry-analysis

Download Free Sample - https://datastringconsulting.c....om/downloadsample/ni

About DataString Consulting

DataString Consulting delivers a comprehensive suite of market research and business intelligence solutions for both B2B and B2C sectors all under one roof. From precise, targeted insights to fully customized market research reports, our services are built to align with each client’s strategic goals. With a leadership team boasting over 30 years of combined experience serving Fortune 500 companies, we offer high-impact research and data services across global markets.

Our service portfolio is designed to support organizations of all sizes. As pioneers of a collaborative and cost-efficient model, we are shaping a sustainable ecosystem where market research firms, consultancies, and corporate teams can access reliable, decision-ready insights—without the overhead of traditional research operations.

Contact:
Mr. Mark Lawson
DataString Consulting
mlawson@datastringconsulting.com
sales@datastringconsulting.com

Niraparib Market Report 2025 | Trends, Analysis & Forecast

Niraparib Market to grow from $1.3B in 2024 to $2.0B by 2030 with 7.1% CAGR; Hospitals and Pharmacies End-Users to capture larger market share.